PT - JOURNAL ARTICLE AU - Sanjoy Roychowdhury AU - Piyush M. Vyas AU - Craig K. Svensson TI - Formation and Uptake of Arylhydroxylamine-Haptenated Proteins in Human Dendritic Cells AID - 10.1124/dmd.106.013680 DP - 2007 Apr 01 TA - Drug Metabolism and Disposition PG - 676--681 VI - 35 IP - 4 4099 - http://dmd.aspetjournals.org/content/35/4/676.short 4100 - http://dmd.aspetjournals.org/content/35/4/676.full SO - Drug Metab Dispos2007 Apr 01; 35 AB - Bioactivation of sulfonamides and the subsequent formation of haptenated proteins is believed to be a critical step in the development of hypersensitivity reactions to these drugs. Numerous lines of evidence suggest that the presence of such adducts in dendritic cells (DCs) migrating to draining lymph nodes is essential for the development of cutaneous reactions to xenobiotics. Our objective was to determine the ability of human DCs to form drug-protein covalent adducts when exposed to sulfamethoxazole (SMX), dapsone (DDS), or their arylhydroxylamine metabolites [sulfamethoxazole hydroxylamine (S-NOH) and dapsone hydroxylamine (D-NOH)] and to take up preformed adduct. Naive and immature CD34+ KG-1 cells were incubated with SMX, DDS, or metabolites. Formation of haptenated proteins was probed using confocal microscopy and ELISA. Cells were also incubated with preformed adduct (drug-bovine serum albumin conjugate), and uptake was determined using confocal microscopy. Both naive and immature KG-1 cells were able to bioactivate DDS, forming drug-protein adducts, whereas cells showed very little protein haptenation when exposed to SMX. Exposure to S-NOH or D-NOH resulted in protein haptenation in both cell types. Both immature and naive KG-1 cells were able to take up preformed haptenated proteins. Thus, DCs may acquire haptenated proteins associated with drugs via intracellular bioactivation, uptake of reactive metabolites, or uptake of adduct formed and released by adjacent cells (e.g., keratinocytes). The American Society for Pharmacology and Experimental Therapeutics